{
  "nodes": [
    {
      "id": "N1",
      "label": "Step 1",
      "customData": {
        "node_id": "A",
        "node_step_index": 0,
        "content": "57-year-old male presented in December 2015 with chest pain and post-activity fatigue.",
        "clinical_data": {
          "HPI": [
            {
              "summary": "57-year-old male presented with chest pain and post-activity fatigue.",
              "onset": "December 2015",
              "associated_symptoms": [
                "chest pain",
                "post-activity fatigue"
              ]
            }
          ]
        }
      }
    },
    {
      "id": "N2",
      "label": "Step 2",
      "customData": {
        "node_id": "B",
        "node_step_index": 1,
        "content": "Diagnosed with left lower lung adenocarcinoma (cT1N2M1a stage IVA) upon identification of cancer cells in his left pleural effusion. NGS of the paraffin-embedded section from pleural effusion revealed an ALK-positive mutation (EML4-ALK fusion).",
        "clinical_data": {
          "diagnoses": [
            {
              "code": "C34.3",
              "label": "Malignant neoplasm of lower lobe, bronchus or lung",
              "status": "active",
              "onset_date": null
            },
            {
              "code": "C78.2",
              "label": "Secondary malignant neoplasm of pleura",
              "status": "active",
              "onset_date": null
            }
          ],
          "labs": [
            {
              "test": "Pleural Effusion Cytology",
              "value": "Cancer cells present",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            },
            {
              "test": "NGS of pleural effusion",
              "value": "ALK-positive mutation (EML4-ALK fusion)",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            }
          ],
          "imaging": [
            {
              "type": "Imaging of lung",
              "body_part": "Lung",
              "modality": null,
              "finding": "Adenocarcinoma",
              "impression": "Adenocarcinoma",
              "date": null
            }
          ]
        }
      }
    },
    {
      "id": "N3",
      "label": "Step 3",
      "customData": {
        "node_id": "C",
        "node_step_index": 2,
        "content": "Patient began self-administering crizotinib from 30th December 2015, at a dose of 250 mg twice daily. Complete response to crizotinib observed by January 1, 2016. Bi-monthly follow-ups showed no drug-related adverse effects, including rash or hypertension. Progression-free survival (PFS) was 35 months.",
        "timestamp": "2015-12-30",
        "clinical_data": {
          "medications": [
            {
              "drug": "C0974449",
              "dosage": "250 mg",
              "frequency": "twice daily",
              "modality": "oral",
              "start_date": "2015-12-30",
              "end_date": null,
              "indication": null
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "Complete response to crizotinib",
              "status": "resolved",
              "onset_date": "2016-01-01"
            }
          ],
          "HPI": [
            {
              "summary": "Progression-free survival (PFS) was 35 months.",
              "duration": "35 months",
              "onset": null,
              "progression": null,
              "associated_symptoms": [],
              "alleviating_factors": [],
              "exacerbating_factors": []
            }
          ],
          "allergies": [
            {
              "substance": "C0974449",
              "reaction": "Drug-related adverse effects",
              "severity": "mild",
              "date_recorded": null
            }
          ],
          "ROS": [
            {
              "system": "constitutional",
              "findings": [
                "No rash"
              ]
            },
            {
              "system": "cardiovascular",
              "findings": [
                "No hypertension"
              ]
            }
          ]
        }
      }
    },
    {
      "id": "N4",
      "label": "Step 4",
      "customData": {
        "node_id": "D",
        "node_step_index": 3,
        "content": "On November 16, 2018, chest ultrasound indicated massive left pleural effusion, discovered during evaluation for post-activity fatigue. Cytological examination of the pleural effusion found cancer cells. CT scan showed a 1.3 cm nodule in the left lung lower lobe. Disease progression (PD) was assessed. Circulating tumor DNA sequencing from plasma sample showed no ALK related mutations.",
        "timestamp": "2018-11-16",
        "clinical_data": {
          "imaging": [
            {
              "type": "Pleural effusion",
              "body_part": "Pleural cavity",
              "modality": "Ultrasound",
              "finding": "massive left pleural effusion",
              "date": "2018-11-16"
            },
            {
              "type": "Nodule",
              "body_part": "Lung lower lobe",
              "modality": "CT",
              "finding": "1.3 cm nodule in the left lung lower lobe",
              "date": "2018-11-16"
            }
          ],
          "labs": [
            {
              "test": "Cytological examination",
              "value": "cancer cells",
              "unit": null,
              "flag": "abnormal",
              "timestamp": "2018-11-16"
            },
            {
              "test": "Circulating tumor DNA sequencing",
              "value": "no ALK related mutations",
              "unit": null,
              "flag": "normal",
              "timestamp": "2018-11-16"
            }
          ],
          "HPI": [
            {
              "summary": "post-activity fatigue",
              "onset": null,
              "progression": "unknown",
              "associated_symptoms": [],
              "alleviating_factors": [],
              "exacerbating_factors": []
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "Disease progression",
              "status": "active",
              "onset_date": null
            }
          ]
        }
      }
    },
    {
      "id": "N5",
      "label": "Step 5",
      "customData": {
        "node_id": "E",
        "node_step_index": 4,
        "content": "DNA sequencing of paraffin-embedded section from pleural effusion revealed the ALK point mutation (F1174C exon23) on Illumina high-throughput sequencing platform. Crizotinib was switched to alectinib at a dose of 600 mg twice daily. Complete Response (CR) achieved on alectinib.",
        "timestamp": "2018-12-04",
        "clinical_data": {
          "labs": [
            {
              "test": "DNA sequencing",
              "value": "ALK point mutation (F1174C exon23)",
              "unit": null,
              "flag": "abnormal",
              "reference_range": null,
              "timestamp": null
            }
          ],
          "medications": [
            {
              "drug": "Crizotinib",
              "dosage": null,
              "frequency": null,
              "modality": null,
              "start_date": null,
              "end_date": null,
              "indication": null
            },
            {
              "drug": "Alectinib",
              "dosage": "600 mg",
              "frequency": "twice daily",
              "modality": "oral",
              "start_date": null,
              "end_date": null,
              "indication": null
            }
          ],
          "diagnoses": [
            {
              "code": null,
              "label": "Complete Response (CR)",
              "status": "resolved",
              "onset_date": null
            }
          ]
        }
      }
    }
  ],
  "edges": [
    {
      "from": "N1",
      "to": "N2",
      "data": {
        "edge_id": "A_to_B",
        "branch_flag": true,
        "content": "From initial symptoms to diagnosis of lung adenocarcinoma and ALK mutation.",
        "transition_event": {
          "trigger_type": "lab_change",
          "trigger_entities": [
            "C0006826",
            "C0547178"
          ],
          "change_type": "addition",
          "target_domain": "diagnosis"
        }
      }
    },
    {
      "from": "N2",
      "to": "N3",
      "data": {
        "edge_id": "B_to_C",
        "branch_flag": true,
        "content": "Initiation of crizotinib treatment and subsequent complete response.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0974449"
          ],
          "change_type": "addition",
          "target_domain": "medication",
          "timestamp": "2015-12-30T00:00:00Z"
        }
      }
    },
    {
      "from": "N3",
      "to": "N4",
      "data": {
        "edge_id": "C_to_D",
        "branch_flag": true,
        "content": "Disease progression indicated by pleural effusion and nodule, with no ALK mutations detected in circulating tumor DNA.",
        "transition_event": {
          "trigger_type": "symptom_onset",
          "trigger_entities": [
            "C0032285"
          ],
          "change_type": "progression",
          "target_domain": "symptom",
          "timestamp": "2018-11-16T00:00:00Z"
        }
      }
    },
    {
      "from": "N4",
      "to": "N5",
      "data": {
        "edge_id": "D_to_E",
        "branch_flag": true,
        "content": "Identification of ALK point mutation (F1174C exon23), switch to alectinib, and achievement of complete response.",
        "transition_event": {
          "trigger_type": "medication_change",
          "trigger_entities": [
            "C0974449",
            "C1699728"
          ],
          "change_type": "addition",
          "target_domain": "medication"
        }
      }
    }
  ]
}